3rd Rare & Genetic Kidney Disease Drug Development Summit 2023
Accelerating the Development of Therapeutic Treatments for IgAN, FSGS, Alport Syndrome, PKD & More!
80+ experts joined from the FDA, EMA, Eloxx Pharmaceuticals, HI-Bio, Chinook Therapeutics, Novo Nordisk, Janssen, Travere Therapeutics, Otsuka, Sanofi and many more to:
- Leverage genetic, transcriptomic, and proteomic profiling to identify future indications
- Incorporate real-world evidence into trial planning to reduce the barriers to clinical trial diversity
- Better understand patients’ experiences to ameliorate clinical trial design
- Navigate endpoints beyond total kidney volume and eGFR slope during earlier phases of drug development for efficient assessment of clinical signal